Liraglutide Dosing Schedule: Titration, Timing, and Missed Doses

Liraglutide at a glance:

• Drug class: GLP-1 receptor agonist
• Manufacturer: Novo Nordisk
• FDA approved: 2010
• Route: subcutaneous injection
• Typical frequency: once daily
• Half-life: approximately 13 hours
• Cash price (US): $1,200-$1,400/month without insurance
• Receptor target: GLP-1 receptor

Most people who quit Liraglutide do it during titration, and most of those quits trace to dosing decisions. Get the schedule right and the rest is much easier.

Standard Dosing Schedule for Liraglutide

Liraglutide is titrated weekly from a starting dose to the target dose to minimize gastrointestinal side effects. Saxenda's target dose for weight management is 3.0 mg/day; Victoza's target for diabetes is 1.8 mg/day. Titration over 4-5 weeks is standard.

The typical schedule for Liraglutide is once daily via subcutaneous injection. Half-life of approximately 13 hours explains why this schedule works — the drug stays active long enough to support that interval.

Titration: Why Starting Low Matters

For incretin therapies, gradual titration is the standard approach. The starting doses listed above are not therapeutic — they exist to let the body adapt and to reduce gastrointestinal symptoms (nausea, vomiting, diarrhea).

A typical titration plan for Liraglutide holds each dose step for at least four weeks before moving up. Faster titration is associated with more dropouts due to side effects.

Missed Doses

If a dose of Liraglutide is missed: for daily schedules, the rule of thumb is to take it as soon as remembered if within a defined window, otherwise skip it and resume the regular schedule. The exact window depends on the half-life (approximately 13 hours) and the specific product label. Never double up to make up for a missed dose.

Dose Adjustments

Dose adjustments may be needed for the following:

• Significant weight loss or weight gain
• Side-effect intolerance at the current step
• Changes in renal or hepatic function
• Drug interactions (particularly relevant for any concurrent medications)

We cover the side-effect side of dose decisions in Liraglutide side effects and the cost angle of dose escalation in Liraglutide cost.

What the Trials Used

Published trial data for Liraglutide comes primarily from: SCALE Obesity and Prediabetes trial (Pi-Sunyer 2015, NEJM) — 9.2% mean weight loss at 56 weeks vs 3.5% on placebo.

That data drives the labeled dosing range, which is what physicians prescribe by.

Special Populations

The dosing guidance above applies to general adult use. Special populations — pregnancy, pediatric, severe renal impairment, hepatic dysfunction, elderly with frailty — require individualized assessment that this page can't substitute for.

For Liraglutide: the personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, prior serious hypersensitivity apply.

Bottom Line

Dosing Liraglutide is a long game. Get the titration right, hold steady, and adjust deliberately based on how your body responds.

Frequently Asked Questions

Related Reading

• Liraglutide Explained: How It Works and Who It's For
• Liraglutide Side Effects: The Complete List and How to Handle Them
• Real Liraglutide Results: What 6 and 12 Months Actually Look Like
• The Real Liraglutide Price Tag in 2026 — With and Without Insurance
• Dulaglutide Explained: How It Works and Who It's For
• What Is Exenatide? Everything You Should Know Before Starting

Sources

• Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). NEJM 2015;373:11.
• Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM 2023;389:2221.
• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989.

This page is informational only and is not medical advice. Always follow your prescribing clinician's dosing instructions.